# A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome

> **NCT05411718** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 40 (estimated)

## Conditions studied

- T Cells
- Colorectal Cancer
- Lynch Syndrome

## Interventions

- **DRUG:** Naproxen
- **DRUG:** Aspirin

## Key facts

- **NCT ID:** NCT05411718
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-21
- **Primary completion:** 2026-11-30
- **Final completion:** 2026-11-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-11-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05411718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05411718, "A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT05411718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*